Halozyme Therapeutics, Inc. - Common Stock
|Range Today||$19.52 - $20.91|
|52 Week Range||$9.68 - $20.91|
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.